Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development
Reference number: GID-TA10832
Expected publication date: TBC
Further to the commercial discussions between the company and NHS England, this appraisal will remain paused until NICE has the power to apply the new cost-effectiveness threshold. NICE anticipates that its cost-effectiveness threshold will increase in April 2026 and we will provide a further update to stakeholders at that time. More information about changes to NICE’s cost-effectiveness thresholds can be found here: https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed